REFERENCES
- Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA. Cancer J Clin. 2005; 55(1)10–30, [INFOTRIEVE], [CSA]
- Gronberg H. Prostate cancer epidemiology. Lancet. 2003; 361(9360)859–864, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jani A. B., Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003; 361(9362)1048–1053, [CROSSREF], [CSA]
- Laupacis A., Sackett D. L., Roberts R. S. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 1988; 318(26)1728–1733, [INFOTRIEVE], [CSA]
- Cook R. J., Sackett D. L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310(6977)452–454, [PUBMED], [INFOTRIEVE], [CSA]
- Cordell D L. Number needed to treat (NNT). Ann. Emerg. Med. 1999; 33(4)433–436, [INFOTRIEVE], [CROSSREF], [CSA]
- Labbe K. A., Detsky A. S., O'Rourke K. Meta-analysis in clinical research. Ann. Intern. Med. 1987; 107(2)224–233, [CSA]
- Richardson A. Screening and the number needed to treat. J. Med. Screen. 2001; 8(3)125–127, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boomsma L. J., van Lidth de Jeude C. P. ‘Number needed to screen’: a tool for assessment of prevention programs. Ned. Tijdschr. Geneeskd. 2000; 144(49)2345–2348, [INFOTRIEVE], [CSA]
- Cummings S. R., Black D. M., Thompson D. E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24)2077–2082, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Riegelman R., Schroth W. S. Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms. Med. Decis. Making. 1993; 13(3)247–252, [INFOTRIEVE], [CSA]
- Schultzer M., Mancini G. B.J. ‘Unqualified success’ and ‘unmitigated failure’: number needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int. J. of Epidemiol. 1996; 25(4)704–712
- Sinclair J. C., Cook R. J., Guyatt G. H., Pauker S. G., Cook D. J. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J. Clin. Epidemiol. 2001; 54(3)253–262, [CSA]
- Maceneaney P. M., Malone D. E. Applying ‘evidence-based medicine’ theory to interventional radiology. Part 2: a spreadsheet for swift assessment of procedural benefit and harm. Clin. Radiol. 2000; 55(12)938–945, [INFOTRIEVE], [CROSSREF], [CSA]
- Oldridge N., Perkins A., Marchionni N., Fumagalli S., Fattirolli F., Guyatt G. Number needed to treat in cardiac rehabilitation. J. Cardiopulm. Rehabil. 2002; 22(1)22–30, [INFOTRIEVE], [CROSSREF], [CSA]
- Tramer M. R., Reynolds D. J., Stoner N. S., Moore R. A., McQuay H. J. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Eur. J. Cancer. 1998; 34(12)1836–1844, [INFOTRIEVE], [CROSSREF], [CSA]
- Lesaffre E., Boon P., Pledger G. W. The value of the number-needed-to-treat method in antiepileptic drug trials. Epilepsia. 2000; 41(4)440–446, [INFOTRIEVE], [CROSSREF], [CSA]
- Hwang P., Auclair B., Beechinor D., Diment M., Einarson T. R. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology 1997; 50(1)39–43, [INFOTRIEVE], [CROSSREF], [CSA]
- McQuay H. J., Collins S. L., Carroll D., Moore R. A. Radiotherapy for the palliation of painful bone metastases. 2000, Cochrane. Database Syst. Rev., (2), CD001793
- Jani A. B., Basu A., Heimann R., Hellman S. Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer 2003; 97: 359–366, [INFOTRIEVE], [CROSSREF], [CSA]
- Jani A. B., Myrianthopoulos L., Vijayakumar S. The application of number needed to treat (NNT) to clinical problems in radiotherapy. Cancer Invest 2004; 22(2)262–270, [INFOTRIEVE], [CROSSREF], [CSA]
- Abdalla I., Basu A., Hellman S. An evidence-based analysis of the management of localized prostate cancer. Cancer J. 2002; 8(1)40–46, [INFOTRIEVE], [CSA]
- Jani A. B., Kao J., Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer 2003; 98(11)2351–2361, [INFOTRIEVE], [CROSSREF], [CSA]
- Jani A. B., Kao J., Heimann R., Hellman S. Hormone Therapy Adjuvant to External Beam Radiotherapy for Early Prostate Cancer: A Complication-Adjusted Number-Needed to Treat (NNT) Analysis. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61(3)687–694, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jani A. B., Sokoloff M., Shalhav A., Stadler W. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis. Urology 2004; 64(5)976–981, [INFOTRIEVE], [CROSSREF], [CSA]
- Zelefsky M. J., Fuks Z., Happersett L., Lee H. J., Ling C. C., Burman C. M., Hunt M., Wolfe T., Venkatraman E. S., Jackson A., Skwarchuk M., Leibel S. A. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother. Oncol. 2000; 55(3)241–249, [INFOTRIEVE], [CROSSREF], [CSA]
- Grimm P. D., Blasko J. C., Sylvester J. E., Meier R. M., Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51(1)31–40, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Johansson J. E., Holmberg L., Johansson S., Bergstrom R., Adami H. O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277(6)467–471, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jani A. B. The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer. Expert Opin. Pharmacother. 2004; 5(12)2469–2477, [CROSSREF], [CSA]
- Pilepich M. V., Winter K., John M. J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50(5)1243–1252, [INFOTRIEVE], [CROSSREF], [CSA]
- Laverdiere J, Gomez J. L., Cusan L., et al. Beneficial effect of combination hormonal therapy admistered prior and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37(2)247–252, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lawton C. A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49(4)937–946, [INFOTRIEVE], [CROSSREF], [CSA]
- Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360(9327)103–106, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- D'Amico A. V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000; 284(10)1280–1283, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jani A. B., Basu A., Abdalla I., et al. The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate- or high-risk prostate cancer. Am. J. Clin. Oncol. 2003; 26(4)382–385, [INFOTRIEVE], [CROSSREF], [CSA]
- Laverdiere J., Nabid A., De Bedoya L. D., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J. Urol. 2004; 171(3)1137–1140, [INFOTRIEVE], [CROSSREF], [CSA]
- Lee L. N., Stock R. G., Stone N. N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52(2)444–452, [INFOTRIEVE], [CROSSREF], [CSA]
- D'Amico A. V., Whittington R., Malkowicz S. B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280(11)969–974, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Merrick G. S., Butler W. M., Galbreath R. W., Lief J. H., Adamovich E. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?. BJU Int. 2003; 91(1)23–29, [INFOTRIEVE], [CROSSREF], [CSA]
- Potters L., Torre T., Ashley R., Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J. Clin. Oncol. 2000; 18(6)1187–1192, [INFOTRIEVE], [CSA]
- Martinez A, Galalae R, Gonzalez J, et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J. Urol. 2003; 170: 2296–2301, (6 Pt 1)[INFOTRIEVE], [CROSSREF], [CSA]
- D'Amico A. V., Manola J., Loffredo M., Renshaw A. A., DellaCroce A, Kantoff P W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292(7)821–827, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Radiation Therapy Oncology Group, http://www.rtog.orgA Phase IIITrial of the Study of Endocrine Therapy Used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the Prostate (RTOG 94–08)
- Wiegel T., Bressel M., Carl U. M. Adjuvant radiotherapy following radical prostatectomy–results of 56 patients. Eur. J. Cancer 1995; 31A(1)5–11, [INFOTRIEVE], [CROSSREF], [CSA]
- Taylor N. S, Kelly J. F., Kuban D. A., et al. Ajuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56(3)755–763, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- de la Taille A., Flam T. A., Thiounn N., et al. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int. 2002; 90(9)887–892, [INFOTRIEVE], [CROSSREF], [CSA]
- Katz M. S., Zelefsky M. J., Venkatraman E. S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. 2003; 21(3)483–489, [INFOTRIEVE], [CROSSREF], [CSA]
- Eulau S. M., Tate D. J., Stamey T. A., et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998; 41(4)735–740, [INFOTRIEVE], [CROSSREF], [CSA]
- King C. R., Presti J. C., Jr, Gill H., Brooks J., Hancock S. L. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int. J. Radiat. Oncol. Biol. Phys. 2004; 59(2)341–347, [INFOTRIEVE], [CROSSREF], [CSA]
- Song D. Y., Thompson T. L., Ramakrishnan V., et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002; 60(2)281–287, [INFOTRIEVE], [CROSSREF], [CSA]
- Corn B. W., Winter K., Pilepich M. V. Does androgen suppression enhance the efficacy of postoperative irradiation?. A secondary analysis of RTOG 85–31. Urology 1999; 54(3)495–502, [PUBMED], [INFOTRIEVE], [CSA]
- Jani A. B., Kao J. Adjuvant versus salvage post-prostatectomy radiotherapy: a complication-adjusted number needed to treat analysis. Cancer 2005, in press[CSA]
- Tsien C., Griffith K. A., Sandler H. M., et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology. 2003; 62(1)93–98, [INFOTRIEVE], [CROSSREF], [CSA]
- Do L. V., Do T. M., Smith R., Parker R. G. Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am. J. Clin. Oncol. 2002; 25(1)1–8, [INFOTRIEVE], [CSA]
- Catton C., Gospodarowicz M., Warde P., et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol. 2001; 59(1)51–60, [INFOTRIEVE], [CSA]
- Valicenti R. K., Gomella L. G., Ismail M., et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology 1998; 52(6)1034–1040, [INFOTRIEVE], [CROSSREF], [CSA]
- Peschel R. E., Robnett T. J., Hesse D., et al. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int. J. Cancer 2000; 90(1)29–36, [INFOTRIEVE], [CROSSREF], [CSA]
- Nudell D. M., Grossfeld G. D., Weinberg V. K., Roach M, 3rd, Carroll P. R. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999; 54(6)1049–1057, [INFOTRIEVE], [CROSSREF], [CSA]
- Vicini F. A., Ziaja E. L., Kestin L. L., et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999; 54(1)111–117, [INFOTRIEVE], [CROSSREF], [CSA]
- McCarthy J. F., Catalona W. J., Hudson M. A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J. Urol. 1994; 151(6)1575–1578, [INFOTRIEVE], [CSA]
- Taylor N., Kelly J. F., Kuban D. A., Babaian R. J., Pisters L. L., Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56(3)755–763, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kalapurakal J. A., Huang C. F., Neriamparampil M. M., et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54(4)1047–1054, [INFOTRIEVE], [CROSSREF], [CSA]
- Mayer R., Pummer K., Quehenberger F., et al. Postprostatectomy radiotherapy for high-risk prostate cancer. Urology. 2002; 59(5)732–739, [INFOTRIEVE], [CROSSREF], [CSA]
- Morris M. M., Dallow K. C., Zietman A. L., Park J., Althausen A., Heney N. M., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1997; 38(4)731–736, [INFOTRIEVE], [CROSSREF], [CSA]
- Walter S. D., Irwig L. Estimating the number needed to treat (NNT) index when the data are subject to error. Stat. Med. 2001; 20(6)893–906, [INFOTRIEVE], [CROSSREF], [CSA]
- Edwards A., Elwyn G., Hood K., Rollnick S. Judging the ‘weight of evidence’ in systematic reviews: including rigour into the qualitative overview stage by assessing signal and noise. J. Eval. Clin. Pract. 2000; 6(2)177–184, [INFOTRIEVE], [CROSSREF], [CSA]
- Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992; 268(17)2420–2425, [CROSSREF], [CSA]
- Law M. R. The number needed to screen—an adaptation of the number needed to treat. J. Med. Screen 2001; 8(3)114–115, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lee W. R., Is N NT. AOK?. Int. J. Radiation Oncology Biol Phys. 2005; 61(3)640–641, [CROSSREF], [CSA]
- Wu L. A., Kottke T E. Number needed to treat: caveat emptor. J. Clin. Epid. 2001; 54(2)111–116, [CROSSREF], [CSA]
- Kristiansen I. S., Gyrd-Hansen D., Nexoe J., Nielsen J. B. Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J. Clin. Epidemiol 2002; 55(9)888–892, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sheridan S. L., Pignone M. P., Lewis C. L. A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats. J. Gen. Int. Med. 2003; 18(11)884–892, [CROSSREF], [CSA]
- Fletcher R. H., Fletcher S. W. Clinical epidemiology: the essentials, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA 2005
- Dawson-Saunders B., Trapp R. G. Basic and clinical biostatistics. Appleton & Lange, Norwalk, CT 1990